Rhythm Pharmaceuticals announces presentations on setmelanotide

Rhythm Pharmaceuticals (RYTM) announced the presentation of new, real-world data at two European congresses that show consistent improvements in body mass index, BMI-z, and hunger scores in a total of 35 patients with acquired or congenital hypothalamic obesity who were treated with setmelanotide for up to nine months. Physicians from Sorbonne University in Paris delivered two oral presentations with data from patients in the early-access programs in France. At the Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology, the presentation detailed real-world data from 30 patients with acquired hypothalamic obesity on setmelanotide therapy for up to nine months. For the second presentation at the 32nd annual European Congress on Obesity, they also shared data from five patients with congenital hypothalamic obesity, including four patients who reached six months on setmelanotide therapy.